Vipul Organics Limited has secured trading approval from BSE Limited for its preferential equity share allotment, marking a significant milestone in the company's capital expansion plans. The approval enables the trading of newly issued shares to non-promoter investors at a premium pricing.

Trading Approval Details

BSE Limited granted trading approval through letter reference no. LOD/PREF/SV/221/2025-2026 dated March 13, 2026, for the company's preferential share issue. The approval covers specific parameters that demonstrate the structured nature of this capital raising exercise.

Capital Structure Impact

The trading approval will have a direct impact on Vipul Organics Limited's capital structure. Upon the commencement of trading for these preferential shares, the company's listed capital will undergo a significant change.

Regulatory Compliance

The company has fulfilled all regulatory requirements under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The disclosure was made in accordance with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Mansi Shah, Company Secretary & Compliance Officer with Membership No. A35697, signed the regulatory filing on March 13, 2026. The company has also made this information available on its official website at www.vipulorganics.com for stakeholder access.

Exchange Communication

BSE Limited issued Notice No. 20260313-6 dated March 13, 2026 to inform trading members about the listing of these securities. The notice was made available on the exchange's website for the information of all market participants. Marian Dsouza, Assistant Vice President, and Gaurav Bajare, Deputy Manager, signed the official approval letter from BSE Limited confirming the trading commencement.

Vipul Organics Limited has announced robust financial results for Q3FY26, demonstrating strong operational performance alongside its recent fund raising activities. The specialty chemicals company reported significant revenue growth of 16.92% quarter-on-quarter and 11.65% year-on-year, while maintaining compliance with regulatory requirements for its preferential issue fund utilisation.

Q3FY26 Financial Performance

The company delivered impressive quarterly results with total revenue reaching ₹46.38 crore in Q3FY26:

Nine-Month Performance Overview

For the nine months ended December 31, 2025, the company maintained steady growth momentum:

Fund Utilisation Compliance Status

Simultaneously, the company submitted its quarterly compliance statement confirming no deviation in the utilisation of funds raised through preferential issue for the quarter ended December 31, 2025:

The raised funds remain allocated across three primary objectives with no utilisation reported during the quarter - manufacturing facility upgradation and capacity expansion (₹10.66 crore), reduction of long-term bank debts (₹10.00 crore), and general corporate purposes (₹6.88 crore).

Management Outlook

Commenting on the results, Mr. Vipul Shah, Managing Director, highlighted the company's strategic positioning: "We have seen an improvement in our topline in this quarter. With our Capex almost done, we expect the benefits to kick in from the coming quarters. Our water membrane division has also shown traction and we are hopeful of order flow in the coming fiscal."

The company, which ended FY25 with revenues of ₹163 crore, continues to strengthen its position as a leading specialty chemicals manufacturer in the pigments and dyes segment with global presence across over 50 countries.